Austėja Dapkutė
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Austėja Dapkutė has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Julius Juodakis
Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3 shared publications - Justas Trinkūnas
Department of Information Systems, Faculty of Fundamental Sciences, Vilnius Gediminas Technical University, 10223 Vilnius, Lithuania
3 shared publications - Rytis Masiliūnas
Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
3 shared publications - Arvydas Laurinavicius
Vilnius University, Vilnius, Lithuania
2 shared publications - Danguolė Jankauskienė2 shared publications
- Donata Ringaitienė
Vilnius University, Lithuania
2 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e91911
Lithuania’s National Digital Health System Architecture, Evolution, and Lessons From a Centralized Approach Using Longitudinal Document Analysis: Descriptive National Case Study
Background: National digital health systems are increasingly recognized as a key tool for strengthening health care systems and improving patient outcomes. Global guidance from the World Health Organization and European Union initiatives emphasizes interoperability, robust data governance, and secure exchange of health information as prerequisites for system-wide benefits. However, translating these principles into operational national digital health infrastructures remains challenging, and empirical evidence on long-term, centralized implementation models is limited. Lithuania is among a small number of European countries that have implemented a fully centralized national digital health platform (DHP), providing a valuable case for examining the development, structure, and performance of such systems. Objective: This study aimed to describe and analyze Lithuania’s national digital health system across its historical development, governance, technical architecture, interoperability and adoption, and to identify challenges and lessons learned. Methods: We conducted a descriptive national case study of Lithuania’s digital health system using longitudinal document analysis. Publicly available policy documents, legislation, strategy reports, audits, and official statistics published between 2000 and 2025 were systematically reviewed following the readying, extracting, analyzing, and distilling (READ) framework. Thematic analysis was applied to examine governance, system architecture, interoperability, adoption, and implementation challenges. Peer-reviewed literature was used for contextualization. Results: Lithuania’s digital health system evolved from fragmented initiatives in the early 2000s into a fully centralized national DHP that has been operational nationwide since 2015. Since 2018, health care providers have been required to record core clinical data electronically, and all reimbursed medicines are prescribed exclusively through the national electronic prescription system. The DHP integrates electronic health records, electronic prescription system, appointment booking, and other national subsystems with standardized interfaces. System use expanded rapidly: the annual number of electronic documents stored in the DHP increased from approximately 7 million in 2017 to over 100 million in 2024, reflecting widespread uptake of outpatient documentation, referrals, and prescriptions. Patient-facing services, including online access to records and a nationwide appointment booking system, also expanded, although patient-initiated use remains uneven across regions. The platform supports secure primary use for care delivery and secondary use of health data through a centralized access pathway. While core services have reached national scale, some subsystems, such as imaging exchange and telemedicine, remain less mature. Ongoing modernization focuses on improving data interoperability, enabling advanced analytics and future AI-based services, strengthening cross-border eHealth services, and extending coverage to sensitive and previously excluded domains such as mental health, maternal, and newborn care through dedicated subsystems. Conclusions: Lithuania’s centralized digital health system illustrates both the potential and the limitations of national-scale integration driven by legal mandates and standardized interoperability. Its experience provides transferable insights for health systems seeking to consolidate fragmented infrastructures while maintaining data security, regulatory compliance, and long-term system adaptability.
- 2 September 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e91911
Open AccessLithuania’s National Digital Health System Architecture, Evolution, and Lessons From a Centralized Approach Using Longitudinal Document Analysis: Descriptive National Case Study
Background: National digital health systems are increasingly recognized as a key tool for strengthening health care systems and improving patient outcomes. Global guidance from the World Health Organization and European Union initiatives emphasizes interoperability, robust data governance, and secure exchange of health information as prerequisites for system-wide benefits. However, translating these principles into operational national digital health infrastructures remains challenging, and empirical evidence on long-term, centralized implementation models is limited. Lithuania is among a small number of European countries that have implemented a fully centralized national digital health platform (DHP), providing a valuable case for examining the development, structure, and performance of such systems. Objective: This study aimed to describe and analyze Lithuania’s national digital health system across its historical development, governance, technical architecture, interoperability and adoption, and to identify challenges and lessons learned. Methods: We conducted a descriptive national case study of Lithuania’s digital health system using longitudinal document analysis. Publicly available policy documents, legislation, strategy reports, audits, and official statistics published between 2000 and 2025 were systematically reviewed following the readying, extracting, analyzing, and distilling (READ) framework. Thematic analysis was applied to examine governance, system architecture, interoperability, adoption, and implementation challenges. Peer-reviewed literature was used for contextualization. Results: Lithuania’s digital health system evolved from fragmented initiatives in the early 2000s into a fully centralized national DHP that has been operational nationwide since 2015. Since 2018, health care providers have been required to record core clinical data electronically, and all reimbursed medicines are prescribed exclusively through the national electronic prescription system. The DHP integrates electronic health records, electronic prescription system, appointment booking, and other national subsystems with standardized interfaces. System use expanded rapidly: the annual number of electronic documents stored in the DHP increased from approximately 7 million in 2017 to over 100 million in 2024, reflecting widespread uptake of outpatient documentation, referrals, and prescriptions. Patient-facing services, including online access to records and a nationwide appointment booking system, also expanded, although patient-initiated use remains uneven across regions. The platform supports secure primary use for care delivery and secondary use of health data through a centralized access pathway. While core services have reached national scale, some subsystems, such as imaging exchange and telemedicine, remain less mature. Ongoing modernization focuses on improving data interoperability, enabling advanced analytics and future AI-based services, strengthening cross-border eHealth services, and extending coverage to sensitive and previously excluded domains such as mental health, maternal, and newborn care through dedicated subsystems. Conclusions: Lithuania’s centralized digital health system illustrates both the potential and the limitations of national-scale integration driven by legal mandates and standardized interoperability. Its experience provides transferable insights for health systems seeking to consolidate fragmented infrastructures while maintaining data security, regulatory compliance, and long-term system adaptability.
- Open Access
- 24 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Lithuania’s National Digital Health System Architecture, Evolution, and Lessons From a Centralized Approach Using Longitudinal Document Analysis: Descriptive National Case Study (Preprint)
BACKGROUND National digital health systems are increasingly recognized as a key tool for strengthening health care systems and improving patient outcomes. Global guidance from the World Health Organization and European Union initiatives emphasizes interoperability, robust data governance, and secure exchange of health information as prerequisites for system-wide benefits. However, translating these principles into operational national digital health infrastructures remains challenging, and empirical evidence on long-term, centralized implementation models is limited. Lithuania is among a small number of European countries that have implemented a fully centralized national digital health platform (DHP), providing a valuable case for examining the development, structure, and performance of such systems. OBJECTIVE This study aimed to describe and analyze Lithuania’s national digital health system across its historical development, governance, technical architecture, interoperability and adoption, and to identify challenges and lessons learned. METHODS We conducted a descriptive national case study of Lithuania’s digital health system using longitudinal document analysis. Publicly available policy documents, legislation, strategy reports, audits, and official statistics published between 2000 and 2025 were systematically reviewed following the readying, extracting, analyzing, and distilling (READ) framework. Thematic analysis was applied to examine governance, system architecture, interoperability, adoption, and implementation challenges. Peer-reviewed literature was used for contextualization. RESULTS Lithuania’s digital health system evolved from fragmented initiatives in the early 2000s into a fully centralized national DHP that has been operational nationwide since 2015. Since 2018, health care providers have been required to record core clinical data electronically, and all reimbursed medicines are prescribed exclusively through the national electronic prescription system. The DHP integrates electronic health records, electronic prescription system, appointment booking, and other national subsystems with standardized interfaces. System use expanded rapidly: the annual number of electronic documents stored in the DHP increased from approximately 7 million in 2017 to over 100 million in 2024, reflecting widespread uptake of outpatient documentation, referrals, and prescriptions. Patient-facing services, including online access to records and a nationwide appointment booking system, also expanded, although patient-initiated use remains uneven across regions. The platform supports secure primary use for care delivery and secondary use of health data through a centralized access pathway. While core services have reached national scale, some subsystems, such as imaging exchange and telemedicine, remain less mature. Ongoing modernization focuses on improving data interoperability, enabling advanced analytics and future AI-based services, strengthening cross-border eHealth services, and extending coverage to sensitive and previously excluded domains such as mental health, maternal, and newborn care through dedicated subsystems. CONCLUSIONS Lithuania’s centralized digital health system illustrates both the potential and the limitations of national-scale integration driven by legal mandates and standardized interoperability. Its experience provides transferable insights for health systems seeking to consolidate fragmented infrastructures while maintaining data security, regulatory compliance, and long-term system adaptability.
- 24 January 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessLithuania’s National Digital Health System Architecture, Evolution, and Lessons From a Centralized Approach Using Longitudinal Document Analysis: Descriptive National Case Study (Preprint)
BACKGROUND National digital health systems are increasingly recognized as a key tool for strengthening health care systems and improving patient outcomes. Global guidance from the World Health Organization and European Union initiatives emphasizes interoperability, robust data governance, and secure exchange of health information as prerequisites for system-wide benefits. However, translating these principles into operational national digital health infrastructures remains challenging, and empirical evidence on long-term, centralized implementation models is limited. Lithuania is among a small number of European countries that have implemented a fully centralized national digital health platform (DHP), providing a valuable case for examining the development, structure, and performance of such systems. OBJECTIVE This study aimed to describe and analyze Lithuania’s national digital health system across its historical development, governance, technical architecture, interoperability and adoption, and to identify challenges and lessons learned. METHODS We conducted a descriptive national case study of Lithuania’s digital health system using longitudinal document analysis. Publicly available policy documents, legislation, strategy reports, audits, and official statistics published between 2000 and 2025 were systematically reviewed following the readying, extracting, analyzing, and distilling (READ) framework. Thematic analysis was applied to examine governance, system architecture, interoperability, adoption, and implementation challenges. Peer-reviewed literature was used for contextualization. RESULTS Lithuania’s digital health system evolved from fragmented initiatives in the early 2000s into a fully centralized national DHP that has been operational nationwide since 2015. Since 2018, health care providers have been required to record core clinical data electronically, and all reimbursed medicines are prescribed exclusively through the national electronic prescription system. The DHP integrates electronic health records, electronic prescription system, appointment booking, and other national subsystems with standardized interfaces. System use expanded rapidly: the annual number of electronic documents stored in the DHP increased from approximately 7 million in 2017 to over 100 million in 2024, reflecting widespread uptake of outpatient documentation, referrals, and prescriptions. Patient-facing services, including online access to records and a nationwide appointment booking system, also expanded, although patient-initiated use remains uneven across regions. The platform supports secure primary use for care delivery and secondary use of health data through a centralized access pathway. While core services have reached national scale, some subsystems, such as imaging exchange and telemedicine, remain less mature. Ongoing modernization focuses on improving data interoperability, enabling advanced analytics and future AI-based services, strengthening cross-border eHealth services, and extending coverage to sensitive and previously excluded domains such as mental health, maternal, and newborn care through dedicated subsystems. CONCLUSIONS Lithuania’s centralized digital health system illustrates both the potential and the limitations of national-scale integration driven by legal mandates and standardized interoperability. Its experience provides transferable insights for health systems seeking to consolidate fragmented infrastructures while maintaining data security, regulatory compliance, and long-term system adaptability.
- Open Access
- 28 October 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (10)
Migraine in monogenic disorders: Shedding light on new therapeutic targets
Background: Migraine is a common neurological disorder with a strong genetic component, yet the precise mechanisms underlying its genetic susceptibility remain largely unknown. Genome-wide association studies (GWAS) have identified multiple risk loci, but monogenic forms of migraine, particularly Familial Hemiplegic Migraine (FHM), have provided deeper insights into the pathophysiology of migraine. Studying monogenic disorders that present migraine as a symptom could help identify novel therapeutic targets by uncovering shared molecular pathways. Methods: A narrative literature review was conducted using a stepwise approach in the PubMed database. Reviewers were divided into three groups, each focusing on different aspects of migraine genetics. The first group analyzed monogenic migraine syndromes, including FHM and related ion-channelopathies. The second group examined clinical manifestations and phenotypic spectrum of FHM-related genes. The third group expanded the search to other monogenic disorders associated with migraine, such as Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), and Familial Advanced Sleep Phase Syndrome (FASPS). Additional searches were conducted using the Compendium of Causative Genes for Monogenic Disorders. Results: The review identified multiple monogenic disorders associated with migraine, revealing distinct but interconnected mechanisms. Ion-channel dysfunction ( CACNA1A , SCN1A , ATP1A2 ), vascular impairment ( NOTCH3 , TREX1 ), mitochondrial dysfunction ( MT-TL1 ), and circadian dysregulation ( CSNK1D ) emerged as critical contributors to migraine pathophysiology. These findings highlight the roles of neuronal excitability, cortical spreading depression, trigeminal sensitization, and neurovascular dysfunction in migraine. Conclusions: Monogenic migraine disorders offer valuable insights into migraine pathogenesis, emphasizing the importance of ion homeostasis, vascular function, and circadian regulation. Although genetic studies have not yet directly translated into new therapeutic targets, the study and knowledge of these rare conditions is pivotal for neurologists and migraine specialists, as it might improve diagnosis and care, and provide new insights into migraine pathophysiology that may ultimately inform future treatments.
- 28 October 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (10)
Open AccessMigraine in monogenic disorders: Shedding light on new therapeutic targets
Background: Migraine is a common neurological disorder with a strong genetic component, yet the precise mechanisms underlying its genetic susceptibility remain largely unknown. Genome-wide association studies (GWAS) have identified multiple risk loci, but monogenic forms of migraine, particularly Familial Hemiplegic Migraine (FHM), have provided deeper insights into the pathophysiology of migraine. Studying monogenic disorders that present migraine as a symptom could help identify novel therapeutic targets by uncovering shared molecular pathways. Methods: A narrative literature review was conducted using a stepwise approach in the PubMed database. Reviewers were divided into three groups, each focusing on different aspects of migraine genetics. The first group analyzed monogenic migraine syndromes, including FHM and related ion-channelopathies. The second group examined clinical manifestations and phenotypic spectrum of FHM-related genes. The third group expanded the search to other monogenic disorders associated with migraine, such as Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), and Familial Advanced Sleep Phase Syndrome (FASPS). Additional searches were conducted using the Compendium of Causative Genes for Monogenic Disorders. Results: The review identified multiple monogenic disorders associated with migraine, revealing distinct but interconnected mechanisms. Ion-channel dysfunction ( CACNA1A , SCN1A , ATP1A2 ), vascular impairment ( NOTCH3 , TREX1 ), mitochondrial dysfunction ( MT-TL1 ), and circadian dysregulation ( CSNK1D ) emerged as critical contributors to migraine pathophysiology. These findings highlight the roles of neuronal excitability, cortical spreading depression, trigeminal sensitization, and neurovascular dysfunction in migraine. Conclusions: Monogenic migraine disorders offer valuable insights into migraine pathogenesis, emphasizing the importance of ion homeostasis, vascular function, and circadian regulation. Although genetic studies have not yet directly translated into new therapeutic targets, the study and knowledge of these rare conditions is pivotal for neurologists and migraine specialists, as it might improve diagnosis and care, and provide new insights into migraine pathophysiology that may ultimately inform future treatments.
- Open Access
- 11 June 2025
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 54 (4)
Data Resource Profile: The Lithuanian health data reuse pathway
- 11 June 2025
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 54 (4)
Open AccessData Resource Profile: The Lithuanian health data reuse pathway
- Open Access
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 145-152
Artery of Percheron Stroke: A Case Report
Background: The Artery of Percheron (AOP) is a vascular variant supplying both sides of the thalamus, present in up to one-quarter of the general population. AOP occlusion is a rare cause of ischemic stroke, resulting in bilateral thalamic infarction. It typically manifests as altered consciousness, gaze abnormalities, and cognitive impairment. Neuroimaging of AOP stroke is challenging, as head CT is often unremarkable. However, a diagnostic ‘V’ sign can be identified on MRI. AOP stroke is treated as other types of ischemic stroke.Case description: We present a case of a 61-year-old male with a history of alcohol abuse, diagnosed with ischemic AOP stroke. He presented with sudden loss of consciousness, third nerve palsy, and vertical gaze palsy. MRI revealed bilateral paramedian thalamic infarction with midbrain involvement. Despite conservative treatment, his condition showed minimal improvement, leaving him lethargic and dysarthric. He was discharged to palliative care after two weeks.Conclusions: AOP infarction, though rare, should be considered in patients with altered consciousness. Early MRI is essential for accurate diagnosis and timely treatment, highlighting the importance of physician awareness of this condition.
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 145-152
Open AccessArtery of Percheron Stroke: A Case Report
Background: The Artery of Percheron (AOP) is a vascular variant supplying both sides of the thalamus, present in up to one-quarter of the general population. AOP occlusion is a rare cause of ischemic stroke, resulting in bilateral thalamic infarction. It typically manifests as altered consciousness, gaze abnormalities, and cognitive impairment. Neuroimaging of AOP stroke is challenging, as head CT is often unremarkable. However, a diagnostic ‘V’ sign can be identified on MRI. AOP stroke is treated as other types of ischemic stroke.Case description: We present a case of a 61-year-old male with a history of alcohol abuse, diagnosed with ischemic AOP stroke. He presented with sudden loss of consciousness, third nerve palsy, and vertical gaze palsy. MRI revealed bilateral paramedian thalamic infarction with midbrain involvement. Despite conservative treatment, his condition showed minimal improvement, leaving him lethargic and dysarthric. He was discharged to palliative care after two weeks.Conclusions: AOP infarction, though rare, should be considered in patients with altered consciousness. Early MRI is essential for accurate diagnosis and timely treatment, highlighting the importance of physician awareness of this condition.
- 10 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (5) , 3305-3312
Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey
Background Despite development of new therapies, migraine remains an undertreated illness. It is important to understand patients’ preferences and perceptions of using a certain therapy. We present data from a nationwide Lithuanian survey of patients’ experience using erenumab for the treatment of high frequency episodic and chronic migraine. Methods An anonymous internet survey was distributed on February–March 2021 to the members of Migraine Association of Lithuania. All adult respondents who reported using at least one dose of erenumab were included in the study. Results Out of 145 respondents, 75.2% had chronic migraine, and 31.7% had medication overuse headache. Patients received an average of 6 (IQR 4–9) erenumab doses. 93.1% respondents found erenumab effective, and 72.6% experienced improvement during the first month. MHDs were reduced by 9.8 (SD 6.0) (P < 0.001), and MMDs by 7.2 (SD 5.2) days (P < 0.001). 78.6% respondents achieved ≥ 50% reduction and 47.6% achieved ≥ 75% reduction of MMDs. 13.8% patients indicated a wearing-off effect during the treatment course, and 37.8% – some wearing-off between injections. Constipation was the most frequent adverse event (32.6%). 47.2% of patients who had a positive erenumab effect and discontinued treatment experienced migraine rebound in 6 (SD 2.0) weeks. Conclusion Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement. Highlights • Vast majority of patients experience stable or increasing effect of erenumab. • Erenumab efficacy usually becomes evident during the first month of treatment. • Erenumab is perceived significantly better than non-specific preventive medications. • Almost 40% of patients experienced some wearing-off between injections. • Almost half of patients experience migraine rebounds after treatment cessation.
- 10 January 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (5) , 3305-3312
Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey
Background Despite development of new therapies, migraine remains an undertreated illness. It is important to understand patients’ preferences and perceptions of using a certain therapy. We present data from a nationwide Lithuanian survey of patients’ experience using erenumab for the treatment of high frequency episodic and chronic migraine. Methods An anonymous internet survey was distributed on February–March 2021 to the members of Migraine Association of Lithuania. All adult respondents who reported using at least one dose of erenumab were included in the study. Results Out of 145 respondents, 75.2% had chronic migraine, and 31.7% had medication overuse headache. Patients received an average of 6 (IQR 4–9) erenumab doses. 93.1% respondents found erenumab effective, and 72.6% experienced improvement during the first month. MHDs were reduced by 9.8 (SD 6.0) (P < 0.001), and MMDs by 7.2 (SD 5.2) days (P < 0.001). 78.6% respondents achieved ≥ 50% reduction and 47.6% achieved ≥ 75% reduction of MMDs. 13.8% patients indicated a wearing-off effect during the treatment course, and 37.8% – some wearing-off between injections. Constipation was the most frequent adverse event (32.6%). 47.2% of patients who had a positive erenumab effect and discontinued treatment experienced migraine rebound in 6 (SD 2.0) weeks. Conclusion Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement. Highlights • Vast majority of patients experience stable or increasing effect of erenumab. • Erenumab efficacy usually becomes evident during the first month of treatment. • Erenumab is perceived significantly better than non-specific preventive medications. • Almost 40% of patients experienced some wearing-off between injections. • Almost half of patients experience migraine rebounds after treatment cessation.